Salute e Benessere

Casino Group: 2023 Full Year Results

2023 FULL-YEAR RESULTSIn accordance with IFRS 5 – Non-current Assets Held for Sale and Discontinued Operations, the 2022 and 2023 net sales and earnings for Assaí, Grupo Éxito, GPA and the Group's French hypermarkets and supermarkets are presented within discontinued operations. Consequently, the net sales and earnings (including EBITDA and trading profit) presented in this press release relate solely to the Group's continuing operations (Monoprix, Franprix, Casino convenience banners,...
Nasdaq GlobeNewswire
28/02/2024

Nexstim Receives NBS System 5 Order from Neurosurgery Customer in Germany

Press release, Helsinki, 28 February 2024 at 9 AM (EET) Nexstim Receives NBS System 5 Order from Neurosurgery Customer in Germany Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an existing customer. The system will be used in neurosurgery.The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The system provides information…
Nasdaq GlobeNewswire
28/02/2024

Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO

Press Release Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO More than 25 years of experience in senior business development and corporate roles, with over 6 years as Chief Business Officer of Nicox Initial focus on securing financing to complete Phase 3 trial of NCX 470, DenaliFocus on concluding strategic and/or partnership agreements, in particular a licence agreement in the United States for the NCX 470 February 28, 2024 – release at 7:30 am CET...
Nasdaq GlobeNewswire
28/02/2024

Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus…

Press Release Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial Agreement in principle for an amendment to debt agreements for outstanding bondsStreamline corporate structure to focus on the completion of the second NCX 470 Phase 3 trial, Denali; concomitant reduction in the size of the Board of directorsCash runway extended to November 2024Extraordinary General Meeting to be called for 10 April 2024 on first...
Nasdaq GlobeNewswire
28/02/2024

GOLDWIN Becomes Third Japanese Company to Join "The Fashion Pact" to Proactively…

GOLDWIN INC., headquartered in Tokyo, joined in February 2024 "The Fashion Pact," a global initiative for the fashion and textile industry to curtail environmental burdens. GOLDWIN has become the third Japanese company to join the global initiative. GOLDWIN INC., headquartered inTokyo, joined inFebruary 2024"The Fashion Pact," a global initiative for the fashion and textile industry to curtail environmental burdens. GOLDWIN has become the third Japanese company to join the…
PR Newswire
28/02/2024

Idorsia and Viatris enter into a significant global research and development…

Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand...
Nasdaq GlobeNewswire
28/02/2024

Charlotte Hanneman to succeed Abhijit Bhattacharya as Philips' Chief Financial…

Proposal to appoint Ms. Hanneman as member of Philips' Board of Management fulfilling the role of CFO per October 1, 2024Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the proposal to appoint Charlotte Hanneman as member of the Board of Management, fulfilling the role of Chief Financial Officer (CFO), effective October 1, 2024. The proposal will be submitted to the Annual General Meeting of Shareholders...
Nasdaq GlobeNewswire
28/02/2024

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the…

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGeneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority that there was a substantial risk that it will lack the resources to have financial statements...
Nasdaq GlobeNewswire
28/02/2024

Strong data from DSR® proof-of-concept studies in heart failure accepted for…

Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6 th2024Ghent, Belgium – 28 February 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the late-breaking abstract including data from the RED DESERT and SAHARA proof-of-concept studies of the Company's DSR therapy in patients with diuretic-resistant heart...
Nasdaq GlobeNewswire
28/02/2024

Guide Sensmart showcased some significant new products at the British Shooting…

At the exhibition, the audience showed great interest in the new TU Gen2 LRF thermal imaging scope, which they were able to try out firsthand. This product combines a laser rangefinder into a compact design, allowing for precise target detection up to 1500 meters. This feature offers users a dependable way to gauge distances in outdoor settings and enhance shooting accuracy. Additionally, the battery life has been extended by 20%, marking a significant improvement in the device's overall…
PR Newswire
28/02/2024

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune…

Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NCT05947955 ). The study,A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infectionsis being conducted under a contract with BARDA'sD ivision ofR esearch,I nnovation, and...
Nasdaq GlobeNewswire
27/02/2024

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to...
Nasdaq GlobeNewswire
27/02/2024

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:7,325 shares at DKK 1,025.00, 19,631 shares at DKK 1,032.00, 2,473 shares at DKK 1,050...
Nasdaq GlobeNewswire
27/02/2024

Vieworks Unveils Cutting-Edge X-ray Imaging Solutions at ECR 2024

Vieworks' large-format and large-area detector products (VIVIX-S 1751S, VIVIX-S 4747V) are designed to optimize full-spine, half-body, and large-area imaging, offering static image detectors capable of capturing wider area images in a single scan compared to conventional models, thereby reducing patient radiation exposure. With advantages such as high resolution and swift image acquisition, these detectors enable more efficient diagnosis. Vieworks' large-format and large-area detector…
PR Newswire
27/02/2024

More than 6.98 Million Units of Robotic Lawn Mowers to be Sold by 2029, the…

Browse In-Depth TOC on the Robotic Lawn Mower Market Browse In-Depth TOC on the Robotic Lawn Mower Market 755 – Pages 913 - Tables 188 - Figures Global Robotic Lawn Mower Market Report Scope • Growing Marketing Efforts & Promotional Activities • Lower Operational Cost of Robotic Lawn Mowers • Increasing Demand for Golf Courses The landscaping industry is experiencing significant post-pandemic growth, fueling demand for robotic...
PR Newswire
27/02/2024

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaMaxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV approved in CanadaLiège, Belgium – 27 February 2024, 06:00 PM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Hikma...
Nasdaq GlobeNewswire
27/02/2024

TYMPAHEALTH CELEBRATES WORLD HEARING DAY WITH A CALL TO ACTION FOR EAR AND…

In the UK 1 in 5 people are affected by ear and hearing health conditions, often falling to realise that they miss out on certain words and sounds. In the UK 1 in 5 people are affected by ear and hearing health conditions, often falling to realise that they miss out on certain words and sounds. Commonly seen as a sign of ageing, research shows that a social stigma remains prevalent, with people still waiting long periods of time before they get a hearing health assessment – often between...
PR Newswire
27/02/2024

Mice Model Market Worth $2.2 billion | MarketsandMarkets™

Browse in-depth TOC on "Mice Model Market" Browse in-depth TOC on "Mice Model Market" 496 - Tables 46 - Figures 386 - Pages Mice Model Market Scope: The inbred mice segment accounted for the largest share by model type in the mice model market in 2023. By model type, the mice model market has been further categorized into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. Inbred mice accounted for the largest share of the mice model...
PR Newswire
27/02/2024

FutureBridge Report Highlights Evolving Opportunities and Innovation Dynamics in…

Encompassing a diverse spectrum of wounds and ulcers, the report meticulously covers venous, pressure, diabetic foot, traumatic, arterial, mixed, surgical, hematoma, abrasions, avulsions, lacerations, ischemic, and those caused by crush, velocity, and radiation. Notable highlights in the report include: Encompassing a diverse spectrum of wounds and ulcers, the report meticulously covers venous, pressure, diabetic foot, traumatic, arterial, mixed, surgical, hematoma, abrasions, avulsions,...
PR Newswire
27/02/2024

Kotex Global Study Finds Nearly 60% of Women Feel Progress is Lacking and…

"In a long history of advancement of women's rights and equality, today we are reminded that progress isn't a given," said Alison Lewis, chief growth officer at Kimberly-Clark. "Now is a crucial time for women everywhere to use their voices to inspire change, and we are pleased to offer a platform to share what #ProgressFeelsLike from their viewpoint. On International Women's Day and every day, #ProgressFeelsLike unites us and empowers us in our pursuit of progress across every…
PR Newswire
27/02/2024

Aktiia Secures CHF 27 Million (USD 30M) in Funding from Khosla Ventures and…

"Aktiia's commitment to transforming the way blood pressure is treated and understood aligns perfectly with my passion for leveraging technology to address pressing healthcare challenges," said Daniel Graf. "I am excited to join this talented team and contribute to a future where hypertension management is more proactive, data-driven, personalized, and effective." "Aktiia's commitment to transforming the way blood pressure is treated and understood aligns perfectly with…
PR Newswire
27/02/2024

Oxehealth welcomes Todd Haedrich as Chief Executive Officer

Born from over a decade of groundbreaking machine learning and clinical research from one of the world's great research universities, Oxehealth has rapidly become a standard of care for managing acute mental health conditions in England and has been adopted by 50% of providers within the UK's National Health Service (NHS). With over 18 patents and 45 million hours of utilization, and supporting care for over 30 thousand patients, Oxehealth's platform - Oxevision – is a proven solution for…
PR Newswire
27/02/2024

Hedia Raises €3M Seed Extension to Expand Digital Health Portfolio

This exciting news follows the update earlier this week, where Hedia announced their new CEO, Lars Lund. This exciting news follows the update earlier this week, where Hedia announced their new CEO,Lars Lund. Today,Lars Christian Lundsaid about the financial extension, " As I take the reins in Hedia, I am delighted to see the confidence from our investors in our world class team, our existing groundbreaking technology as well as our strong pipeline. Hedia will now be able to build on...
PR Newswire
27/02/2024

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

Mr. Kennedy's appointment reflects Jazz's ongoing focus on Board renewal, and his financial and operating expertise will further enhance the skill set of the Board. Following the departure of Mr. Gray, Jazz's Board will be comprised of twelve directors, four of whom have been appointed in the past five years. Half of Jazz's Board seats are held by members of diverse communities: female, of color, and/or LGBTQIA+. Mr. Kennedy's appointment reflects Jazz's ongoing focus on Board renewal, and…
PR Newswire
27/02/2024
Altri  Comunicati